MeVis Medical Solutions AG (FRA:M3V) Notes Receivable: €0.00 Mil (As of Mar. 2026)


FRA:M3V MeVis Medical Solutions AG FRA:M3V
66 GF Score
Price €24.00
GF Value €22.72
! 5 Warning Signs
View Full Analysis

What is MeVis Medical Solutions AG Notes Receivable?

MeVis Medical Solutions AG FRA:M3V 66 Notes Receivable is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:M3V with a GF Score™ of 66/100 and a GF Value™ of €22.72. The stock has 5 warning signs investors should review.

MeVis Medical Solutions AG's Notes Receivable for the quarter that ended in Mar. 2026 was €0.00 Mil.


MeVis Medical Solutions AG Notes Receivable Related Terms


MeVis Medical Solutions AG Notes Receivable Historical Data

* Premium members only.

The historical data trend for MeVis Medical Solutions AG's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MeVis Medical Solutions AG Notes Receivable Chart

MeVis Medical Solutions AG Annual Data
Trend Dec15 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MeVis Medical Solutions AG Semi-Annual Data
Jun16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:M3V
66GF Score
MeVis Medical Solutions AG FRA:M3V
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MeVis Medical Solutions AG Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
MeVis Medical Solutions AG (FRA:M3V) has a Notes Receivable of €0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on MeVis Medical Solutions AG and its competitors.
Is MeVis Medical Solutions AG's Notes Receivable too high?
MeVis Medical Solutions AG's current Notes Receivable is €0.00 Mil. Overall, MeVis Medical Solutions AG has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does MeVis Medical Solutions AG's Notes Receivable compare to VEEV and BTSG?
MeVis Medical Solutions AG's Notes Receivable of €0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Healthcare Providers & Services company?
A good Notes Receivable depends on the Healthcare Providers & Services industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on MeVis Medical Solutions AG and its competitors. MeVis Medical Solutions AG's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MeVis Medical Solutions AG stock overvalued right now?
MeVis Medical Solutions AG (FRA:M3V) has a current Notes Receivable of €0.00 Mil. The stock's GF Value™ is €22.72, compared to a current price of €24.00 — trading 5.6% above its estimated fair value. The current Notes Receivable is €0.00 Mil. MeVis Medical Solutions AG's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For MeVis Medical Solutions AG (FRA:M3V), the current Notes Receivable is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MeVis Medical Solutions AG (FRA:M3V) Overvalued in 2026?

Based on GuruFocus' analysis, MeVis Medical Solutions AG stock appears to be overvalued. The current stock price of €24.00 is trading 5.6% above its estimated GF Value™ of €22.72.

Key valuation signals for FRA:M3V:

  • Notes Receivable: €0.00 Mil
  • GF Value™: €22.72 vs. price of €24.00 (5.6% above fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the FRA:M3V stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


MeVis Medical Solutions AG Business Description

Other Exchanges 0HI7:UKM3V:Germany
Address Caroline-Herschel-Strasse 1, Bremen, DEU, 28359
MeVis Medical Solutions AG is a provider of medical software products. The company markets its products to equipment manufacturer of medical devices and providers of medical information technology platforms. Its segment includes Digital mammography and Other diagnostics. The Digital mammography segment develops and markets software products which assist in breast diagnostic imaging and intervention. Its Other diagnostics segment consists of digital radiology products. In addition, it also provides the general analysis of radiology images. The company's geographical area of operations includes the United States of America and Europe.
66GF Score

Get the complete analysis for FRA:M3V

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€24.00
Price
€22.72
GF Value